Novo Still Seeking Superior Tresiba Follow-On, Says CSO
Executive Summary
Despite dropping its Phase II oral insulin program in the second half of 2016, Novo Nordisk's chief scientific officer says the company is quietly continuing to explore options for an oral therapy better than its leading insulin option, Tresiba.
You may also be interested in...
Stockwatch: Flat Is The New Black For Lilly And Sanofi
A lackluster fourth-quarter earnings season at least didn't get any worse with the reports of Merck, Lilly, Sanofi and GSK. Flat earnings guidance might be considered to be an improvement on guidance cuts, but financial guidance that depends on currency effects and the absence of generic competition may ultimately be unreliable.
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.
Biocon Stays Upbeat On Oral Insulin Plans
India's largest biopharmaceutical company, Biocon, on May 17 sought to quell any confusion over its oral insulin program, underscoring that it stays confident of the molecule's prospects and is committed to taking it to the next stage of clinical development after the exit of partner Bristol-Myers Squibb (BMS).